Llusern Scientific exhibited the Lodestar UTI testing system outside Europe for the first time in January this year when the company attended Arab Health 2025 as part of the Wales Government pavilion.

AMR is a major healthcare issue in the region and, as in almost every country, suspected UTI is a primary reason for antibiotic prescribing.

Lodestar’s simplicity and accuracy caught the eye of not only the distributors and doctors in attendance but also the marketing team from Healthcare UK who were on the look-out for innovative British companies to spotlight.

Llusern co-founder and CSO, Dr Jeroen Nieuwland, was interviewed by the team from the UK’s Department for Business and Trade where he outlined the role that Lodestar can play in reducing antibiotic prescribing and help impact the growth of AMR in the Middle East and North Africa.

Watch what Jeroen had to say here:  https://www.youtube.com/shorts/RpX85kN7VT4

 

The Lodestar DX analyser and testing system is registered with the European Patent Office (European Patent Application no: 22732302.9) and the US Patent and Trademark Office (no.18/558,490).